Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Suicidal ideation and behavior currently have no quick-acting pharmacological treatments that are suitable for independent outpatient use. Suicidality is linked to mental pain, which is modulated by the separation distress system through endogenous opioids. The authors tested the efficacy and safety of very low dosages of sublingual buprenorphine as a time-limited treatment for severe suicidal ideation. METHOD: This was a multisite randomized double-blind placebo-controlled trial of ultra-low-dose sublingual buprenorphine as an adjunctive treatment. Severely suicidal patients without substance abuse were randomly assigned to receive either buprenorphine or placebo (in a 2:1 ratio), in addition to their ongoing individual treatments. The primary outcome measure was change in suicidal ideation, as assessed by the Beck Suicide Ideation Scale at the end of each of 4 weeks of treatment. RESULTS: Patients who received ultra-low-dose buprenorphine (initial dosage, 0.1 mg once or twice daily; mean final dosage=0.44 mg/day; N=40) had a greater reduction in Beck Suicide Ideation Scale scores than patients who received placebo (N=22), both after 2 weeks (mean difference -4.3, 95% CI=-8.5, -0.2) and after 4 weeks (mean difference=-7.1, 95% CI=-12.0, -2.3). Concurrent use of antidepressants and a diagnosis of borderline personality disorder did not affect the response to buprenorphine. No withdrawal symptoms were reported after treatment discontinuation at the end of the trial. CONCLUSIONS: The time-limited, short-term use of very low dosages of sublingual buprenorphine was associated with decreased suicidal ideation in severely suicidal patients without substance abuse. Further research is needed to establish the efficacy, safety, dosing, and appropriate patient populations for this experimental treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“that buprenorphine—a μ opioid partial agonist—is also effective on suicidal ideas,36”
From Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial (2022) · cites this paper as [36]
In the citing paper
“The kappa opioid receptor system may play a role in negative affect associated with suicidal ideation and may explain the possible antisuicidal effects of the kappa antagonist buprenorphine (139, 140).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [140]
In the citing paper
“probably through modulating emotional pain/psych-ache.”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [140]
In the citing paper
“Compared with placebo, low-dose buprenorphine reduces suicidal ideation in 2 weeks in individuals who have never used opioids (140)”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [140]
In the citing paper
“and may also reduce suicidal ideation (139, 140, 283, 285, 286).”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [140]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Inhibitions, Symptoms and Anxiety
Freud, S. (1936) · The Psychoanalytic Quarterly · doi:10.1080/21674086.1936.11925284 · Cited by 1,764
Hawton, K., & van Heeringen, K. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60372-x · Cited by 1,671
The psychology of suicidal behaviour
O'Connor, R. C., & Nock, M. K. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70222-6 · Cited by 1,193 · cited 3×
“The relationship between suicidalityanddepressioniscomplex(1,2,5,6),andourfindings in this study appear to support the view that suicidal ideation and depression may be distinct, although related, phenomena, at least with respect to their response to pharmacotherapy.”
BackgroundEisenberger, N. I. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3231 · Cited by 1,016 · cited 2×
“Fifth, this study did not assess nonsuicidal selfinjury, which is associated with borderline personality disorder, mental pain, and abnormalities in the endogenous opioid system(23).”
BackgroundLithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis
Cipriani, A., Hawton, K., Stockton, S., & Geddes, J. R. (2013) · BMJ · doi:10.1136/bmj.f3646 · Cited by 920 · cited 1×
“Atypical antipsychotics (8, 9) and lithium (10) have been found to decrease suicidal ideation and/or suicidal behavior in specific patient populations.”
BackgroundThe archaeology of mind: neuroevolutionary origins of human emotions
(2013) · Choice Reviews Online · doi:10.5860/choice.50-3555 · Cited by 794
Self-citationCommentary: Suicide as Psychache
SHNEIDMAN, E. S. (1993) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-199303000-00001 · Cited by 775
Acetaminophen Reduces Social Pain: Behavioral and Neural Evidence
DeWall, C. N., MacDonald, G., Webster, G. D., Masten, C. L., Baumeister, R. F., Powell, C., Combs, D., Schurtz, D. R., Stillman, T. F., Tice, D. M., et al. (2010) · Psychological Science · doi:10.1177/0956797610374741 · Cited by 486
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480 · cited 1×
“Ketamine is effective as a quick-acting treatment for suicidal ideation and depression, but necessitates repeated administration under medical supervision (11, 12).”
Background(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.183 · Cited by 436
Buprenorphine induces ceiling in respiratory depression but not in analgesia
Dahan, A., Yassen, A., Romberg, R., Sarton, E., Teppema, L., Olofsen, E., & Danhof, M. (2006) · British Journal of Anaesthesia · doi:10.1093/bja/ael051 · Cited by 376
Buprenorphine Treatment of Refractory Depression
Bodkin, J. A., Zornberg, G. L., Lukas, S. E., & Cole, J. O. (1995) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199502000-00008 · Cited by 346 · cited 1×
“While higher dosages of buprenorphine than those we used have been found to exert a strong effect on depressive symptoms (26, 27), our findings are in agreement with those of FIGURE4.”
ResultThe borderline patient's intolerance of aloneness: insecure attachments and therapist availability
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.6.752 · Cited by 308
The Interpersonal Dimension of Borderline Personality Disorder: Toward a Neuropeptide Model
Stanley, B., & Siever, L. J. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09050744 · Cited by 289
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Barbui, C., Esposito, E., & Cipriani, A. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.081514 · Cited by 275
Response of the μ-opioid system to social rejection and acceptance
Hsu, D. T., Sanford, B. J., Meyers, K. K., Love, T. M., Hazlett, K. E., Wang, H., Ni, L., Walker, S. J., Mickey, B. J., Korycinski, S. T., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.96 · Cited by 225
Large, M., Smith, G., Sharma, S., Nielssen, O., & Singh, S. P. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01672.x · Cited by 223
Pain and suicidality: Insights from reward and addiction neuroscience
Elman, I., Borsook, D., & Volkow, N. D. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.06.003 · Cited by 219
Panksepp, J., & Watt, D. (2011) · Psychiatry: Interpersonal and Biological Processes · doi:10.1521/psyc.2011.74.1.5 · Cited by 207 · cited 4×
“Its kappa antagonism may enhance its antidepressant action (16, 27).”
BackgroundSelf-citationHsu, D. T., Sanford, B. J., Meyers, K. K., Love, T. M., Hazlett, K. E., Walker, S. J., Mickey, B. J., Koeppe, R. A., Langenecker, S. A., & Zubieta, J.-K. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.185 · Cited by 205 · cited 1×
“Social rejection activates the endogenous opioid system in healthy volunteers (22, 23), and this activation is altered in depressed patients (24).”
BackgroundPsychological pain: A review of evidence
Mee, S., Bunney, B. G., Reist, C., Potkin, S. G., & Bunney, W. E. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.03.003 · Cited by 187
Mechanisms and consequences of widespread random monoallelic expression
Chess, A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3239 · Cited by 186
Troister, T., & Holden, R. R. (2010) · Personality and Individual Differences · doi:10.1016/j.paid.2010.06.006 · Cited by 172
Evaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169
Sanacora, G., & Schatzberg, A. F. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.261 · Cited by 160
Psychotherapeutic Benefits of Opioid Agonist Therapy
Tenore, P. L. (2008) · Journal of Addictive Diseases · doi:10.1080/10550880802122646 · Cited by 143
Dr. Meltzer and Mr. Cola Reply
Meltzer, H. Y., & Cola, P. A. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.1.153 · Cited by 139
Reeves, H., Batra, S., May, R. S., Zhang, R., Dahl, D. C., & Li, X. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0805 · Cited by 102 · cited 2×
“Atypical antipsychotics (8, 9) and lithium (10) have been found to decrease suicidal ideation and/or suicidal behavior in specific patient populations.”
BackgroundResultNeural and Neurochemical Control of the Separation Distress Call
Panksepp, J., Normansell, L., Herman, B. H., Bishop, P., & Crepeau, L. J. (1988) · Springer eBooks · doi:10.1007/978-1-4613-1051-8_15 · Cited by 102
Self-citationBrodbelt, D. C., Taylor, P. M., & Stanway, G. W. (1997) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1046/j.1365-2885.1997.00060.x · Cited by 65
Additional support for the reliability and validity of the Modified Scale for Suicide Ideation.
Clum, G. A., & Yang, B. (1995) · Psychological Assessment · doi:10.1037//1040-3590.7.1.122 · Cited by 57
Buprenorphine—Clinically useful but often misunderstood
Butler, S. (2013) · Scandinavian Journal of Pain · doi:10.1016/j.sjpain.2013.05.004 · Cited by 47 · cited 4×
“It is a partial mu agonist and a potent kappa antagonist, and it has several active metabolites (32).”
BackgroundInfluentialTreating Suicidality in Depressive Illness. Part 2: Does Treatment Cure or Cause Suicidality?
Sakinofsky, I. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/07067437070526s108 · Cited by 21
- Medication in Suicide Prevention: Insights from Neurobiology of Suicidal Behavior
Dwivedi, Y. (2012) · CRC Press eBooks · doi:10.1201/b12215-27 · Cited by 15
Psychopharmacologic Management of Suicidality in Personality Disorders
Cardish, R. J. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/07067437070526s110 · Cited by 15
Dwivedi, Y. (2012) · CRC Press eBooks · doi:10.1201/b12215-22 · Cited by 7
Richards, B. M. (1999) · British Journal of Guidance and Counselling · doi:10.1080/03069889908259717 · Cited by 6
Scale for Suicide Ideation: Psychometric properties of a self-report version
Beck, A. T., Steer, R. A., & Ranieri, W. F. (1988) · Journal of Clinical Psychology · doi:10.1002/1097-4679(198807)44:4<499::aid-jclp2270440404>3.0.co;2-6
Research works printed but not linked: 4
- Bowlby J. Loss: Sadness and Depression (Attachment and Loss, vol 3; International Psycho-Analytical Library, No 109). London, Hogarth Press, 1980
- 10.1037/1040-3590.7.1.122 · doi:10.1037/1040-3590.7.1.122 · Paper page
- Beck AT, 1996, Manual for the Beck Depression Inventory–II
- Cull JG, 1988, Suicide Probability Scale Manual
Cited by
Turecki, G., Brent, D. A., Gunnell, D., O’Connor, R. C., Oquendo, M. A., Pirkis, J., & Stanley, B. H. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0121-0 · Cited by 1,074
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
“Moreover, buprenorphine, a mu opioid receptor partial agonist and a kappa opioid receptor antagonist, has been shown to produce antidepressant effects (41, 42), even in individuals who have failed to benefit from ECT (43).”
Anhedonia is associated with suicidal ideation independently of depression: A meta-analysis
Ducasse, D., Loas, G., Dassa, D., Gramaglia, C., Zeppegno, P., Guillaume, S., Olié, E., & Courtet, P. (2018) · Depression and Anxiety · doi:10.1002/da.22709 · Cited by 269
“Buprenorphine (a partial 𝜇 opioid agonist) reduces psychological pain and suicidal ideation (Yovell et al., 2016).”
BackgroundA brain-centric model of suicidal behavior
Mann, J. J., & Rizk, M. M. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081224 · Cited by 214
Psychological pain, depression, and suicide: Recent evidences and future directions
Conejero, I., Olié, E., Calati, R., Ducasse, D., & Courtet, P. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0893-z · Cited by 206
Metadata
- Authors
- Yovell, Y., Bar, G., Mashiah, M., Baruch, Y., Briskman, I., Asherov, J., Lotan, A., Rigbi, A., & Panksepp, J.
- Affiliations
- Wolfson Medical Center (IL)
- Venue
- American Journal of Psychiatry
- Published
- 2016-05-01
- Volume
- 173
- Issue
- 5
- Pages
- 491-498
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2202695658
- Cited by
- 311
- References
- 39
- Citations by year
- 2026: 11 · 2025: 24 · 2024: 19 · 2023: 14 · 2022: 24 · 2021: 59 · 2020: 36 · 2019: 28 · 2018: 49 · 2017: 22 · 2016: 22
- FWCI
- 39.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- buprenorphine, suicidal ideation, sublingual administration, time-limited therapy, endogenous opioids, separation distress, adjunctive pharmacotherapy, borderline personality disorder, antidepressants, suicide prevention
- MeSH terms
- Administration, Sublingual, Adult, Mental Disorders, Buprenorphine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Narcotic Antagonists, Psychotropic Drugs, Time Factors, Treatment Outcome, Young Adult, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.